13 results about "Ginsenoside Rh2" patented technology

The application discloses a method for biosynthesizing ginsenoside by using tobacco BY-2 cells as a chassis, and belongs to the technical field of bioengineering. The method comprises the following steps: firstly, a recombinant expression vector containing a key gene set of a ginsenoside synthesis pathway is constructed, wherein the gene set comprises tHMGR, SE, SS and other genes derived from Panax ginseng and Pn1-31 and Pn3-31 genes derived from Panax notoginseng; secondly, the recombinant vector is introduced into tobacco BY-2 cells, and a pure positive cell line is obtained through solid culture medium screening; finally, the positive cell line is cultured in liquid or solid culture medium to obtain ginsenoside Rh2 and / or Rg3. The application successfully reconfigures a rare ginsenoside synthesis pathway by taking advantage of the fast growth and stable culture of tobacco BY-2 cells, realizes efficient heterologous synthesis of the rare ginsenoside, and provides a repeatable technical scheme for industrial production of the rare ginsenoside.

The invention belongs to the technical field of biology and new medicine, and discloses a preparation method of acoustic resonance driven glycyrrhizic acid nano-composite responsive gel, glycyrrhizic acid is used as a drug carrying system, berberine, ursolic acid, baicalein, luteolinin, curcumin, baicalin or ginsenoside Rh2 is used as a water-insoluble natural small molecule drug, and the acoustic resonance driven glycyrrhizic acid nano-composite responsive gel is prepared. Glycyrrhizic acid is an amphiphilic compound composed of one molecule of glycyrrhetinic acid and two molecules of glucuronic acid, a hydrophobic cavity can be formed in a water environment to wrap the water-insoluble natural small molecule medicine, a glycyrrhizic acid nano-composite solution is formed, and meanwhile the solubility of the water-insoluble natural small molecule medicine such as baicalein is improved.

The application provides a method for simultaneously enriching rare ginsenosides by co-fermentation of Eurotium cristatum and Panax ginseng and a fermentation product, wherein the Eurotium cristatum is inoculated into a fermentation substrate containing the root of Panax ginseng, and solid fermentation is carried out; the fermentation product contains ginsenosides Rg2, Rg3 and Rh2; the contents of the three rare ginsenosides Rg2, Rg3 and Rh2 in the fermented Panax ginseng raw material are simultaneously improved; the content of Rg2 ginsenoside is increased to about 1.7 times of the original content; the content of Rg3 ginsenoside is increased to about 1.7 times of the original content; and a new ginsenoside Rh2 is obtained, so that the nutritional value and medicinal efficacy of Panax ginseng are increased.

The invention provides a strain of P.adami Sys-Gs-003 for producing ginsenoside Rh2, the strain is preserved in the China Center for Type Culture Collection, the preservation date is December 4, 2025, the preservation number is CCTCC NO: M20252779, the preservation number is CCTCC NO: M20252779, the preservation number is CCTCC NO: M2025279, and the preservation number is CCTCC NO: M2025279. The 16S rDNA (ribosomal deoxyribonucleic acid) sequence of the strain is as shown in SEQ ID NO. 1. The Prussella adamsii Sys-Gs-003 strain provided by the invention can produce ginsenoside Rh2 through metabolism, can be subjected to large-scale fermentation culture in a short time, is relatively low in fermentation cost, is not limited by conditions such as time domain, season and the like, and has remarkable advantages. Meanwhile, the invention also provides optimized microbial fermentation conditions and a formula of the culture medium, and the yield of the ginsenoside Rh2 is relatively high.

This invention discloses a method for generating rare ginsenoside Rh2, comprising the following steps: adding common diol-type ginsenosides to Aspergillus brasiliensis fermentation broth for fermentation, sterilizing after fermentation to obtain the fermentation product; then enzymatically hydrolyzing with β-glucanase and pectinase, and inactivating the enzymes after hydrolysis to obtain rare ginsenoside Rh2. This invention also provides the rare ginsenoside Rh2 obtained by this method and its applications. This invention utilizes the synergistic effect of Aspergillus brasiliensis, β-glucanase, and pectinase to efficiently and rapidly convert common diol-type ginsenosides into rare ginsenoside Rh2. It has the advantages of simple preparation method, ease of implementation, low cost, and environmental friendliness. The generated rare ginsenoside Rh2 exhibits excellent skin-care and repairing effects and has broad market prospects for application in cosmetics.

The present application provides a ginsenoside-protein peptide complex for nutritional support of cancer patients, and a preparation method and application thereof, and belongs to the technical field of post-chemotherapy nutritional support.The present application comprises ginsenoside Rg3 5-7 parts, ginsenoside Rh2 2-4 parts, Compound K 0.5-1.5 parts, whey protein peptide 80-120 parts, marine fish scale peptide 25-40 parts, beta-glucan 8-12 parts, nano-curcumin 15-25 parts, HMB 20-30 parts, sodium butyrate 35-50 parts, N-acetylcysteine 40-60 parts, vitamin C 40-60 parts, and selenium yeast 0.6-1 part by weight.The present application can play an anti-tumor auxiliary role, provide nutritional support for cancer patients after chemotherapy, reduce the side effects of chemotherapy, and improve the quality of life.

The invention belongs to the technical field of enzyme engineering, and discloses a fusion enzyme for producing rare ginsenoside Rh2 and a preparation method and application thereof. The active part of the fusion enzyme is obtained by sequentially connecting beta-glucosidase Bglpm, a connecting peptide and beta-glucosidase Bgp1. Two enzymes are fused into one enzyme molecule through a gene fusion technology, and the fusion enzyme obtained after screening and optimization effectively improves the catalytic efficiency of the enzyme, so that the reaction rate of converting ginsenoside Rd into rare ginsenoside Rh2 is remarkably improved, the fusion enzyme simplifies the catalytic process, reduces the reaction steps and reaction time, and is suitable for industrial production. And the production efficiency can be improved and the production cost can be reduced.

The invention is suitable for the technical field of biological medicine, and provides a cell microvesicle based on freezing extraction and an extraction method and application thereof, ginsenoside Rh2 is used for pre-stimulating human umbilical cord mesenchymal stem cells (hUC-MSCs), a freezing extraction technology is used for extracting cell-derived frozen microvesicles (CDCs), and the novel engineered vesicles Rh2-CDCs are prepared. The method can effectively improve in-vivo blood coagulation and fibrinolytic system functions, reduce multi-organ injury, improve the treatment effect and improve the biological stability of nano-drug treatment, and the freezing extraction technology not only greatly shortens the extraction time and reduces the production cost, but also can obtain the microvesicles with higher concentration, so that the microvesicles have better application prospects. The technical bottleneck of the traditional exosome in application is expected to be overcome; besides, the freezing extraction technology is also suitable for vesicle extraction of other types of cells, and the extracted CDCs can be used as a nano-particle platform to deliver other drugs and active ingredients, so that the freezing extraction method has a wide application prospect.

The application belongs to the field of drug delivery and particularly relates to a composite porous stent, a composite porous drug delivery system and application. The composite porous stent comprises crosslinked oxidized hyaluronic acid, methacrylated xanthan gum, gelatin and sodium alginate; the composite porous drug delivery system is constructed by loading hyaluronic acid-coated quercetin and ginsenoside Rh2 nanoparticles on the composite porous stent, and can precisely and targetedly deliver the loaded traditional Chinese medicine components to a lesion site, so as to achieve the purpose of high-efficiency, safe and targeted treatment of breast cancer.

The invention discloses a method for converting panoxadiol into ginsenoside Rh2, belongs to the field of natural product chemistry and medicinal chemistry, and particularly relates to a method for converting inactive main components in traditional Chinese medicines into active components. The invention provides a ginseng glycosyl transferase mutant and application thereof. Compared with an amino acid sequence SEQ ID No.1, the amino acid sequence of the mutant is as shown in SEQ ID No.1; in an amino acid sequence SEQ ID No.1, eight sites of S144, Y231, G275, T304, H334, A375, R415, Q445 and the like are respectively subjected to three combined mutations, four combined mutations, four combined mutations, five combined mutations, six combined mutations, seven combined mutations or one of eight combined mutations; the novel ginseng glycosyl transferase mutant industrial enzyme is used for directly converting panaxadiol in ginseng into high-activity ginsenoside Rh2. The ginseng glycosyl transferase mutant enzyme constructed by the invention has the characteristics of low enzyme cost, short conversion time, simple process operation and the like, and has a wide prospect of large-scale industrial application.

The application discloses a medicine containing ginsenoside Rh2 in the field of medicine and a preparation method and application thereof in treating kidney diseases, and relates to a medicine containing ginsenoside Rh2 and two novel derivatives of ginsenoside Rh2, one of which is a kidney-targeting prodrug derivative formed by conjugating polyethylene glycol to the glycosyl of saponin through a cleavable linker, and the other is an anti-pyroptosis derivative in which a sulfate group is introduced into the glycosyl of saponin. The preparation method comprises synthesizing the two derivatives respectively, mixing them with the prototype ginsenoside Rh2 and pharmaceutical excipients, dissolving, adjusting the pH value, filtering, sub-packaging and freeze-drying to prepare a freeze-dried powder injection. The medicine composition significantly enhances the anti-inflammatory, cell pyroptosis inhibition and anti-fibrosis effects on kidney diseases through the synergistic effect of multiple active ingredients, improves the water solubility and targeting of the medicine, and provides a new effective scheme for treating chronic kidney diseases such as diabetic nephropathy.

The invention discloses puerarin lipidosome with ginsenoside Rh2 as a lipid membrane material and a preparation method and application of the puerarin lipidosome, the membrane material cholesterol of the lipidosome is replaced with the lipidosome (Rh2-Pue-LP) of ginsenoside Rh2 de-entrapped puerarin, the Rh2-Pue-LP can inhibit and activate a JAK2-STAT3 signal channel, so that transcription of NLRP3 is inhibited, and the lipidosome has the advantages that the lipidosome can be used for preparing the puerarin lipidosome with the ginsenoside Rh2 as the lipid membrane material; the traditional Chinese medicine composition can be used for inhibiting microglial cell activation and neuronal apoptosis, effectively penetrating through a complete blood brain barrier (BBB), reaching a focus part and playing a role in neuroprotection.

The invention provides a bacillus cereus Sys-Gs-004 strain for producing ginsenoside Rh2, the strain is preserved in China Center for Type Culture Collection, the preservation date is December 4, 2025, the preservation number is CCTCC NO: M20252780, the preservation number is CCTCC NO: M20252780, the preservation number is CCTCC NO: M20252780, and the preservation number is CCTCC NO: M20252780. The 16S rDNA (ribosomal deoxyribonucleic acid) sequence of the strain is as shown in SEQ ID NO. 1. The bacillus cereus Sys-Gs-004 strain provided by the invention can produce ginsenoside Rh2 through metabolism, can be subjected to large-scale fermentation culture in a short time, is relatively low in fermentation cost, is not limited by conditions such as time domain and season, and has remarkable advantages. Meanwhile, the invention also provides optimized microbial fermentation conditions and a formula of the culture medium, and the yield of the ginsenoside Rh2 is relatively high.